Abstract
We hypothesized that non-proliferating (quiescent) human vascular endothelial cells would not express somatostatin receptor subtype 2 (sst 2) and that this receptor would be expressed when the endothelial cells begin to grow. To test this hypothesis, placental veins were harvested from 6 human placentas and 2 mm vein disks were cultured in 0.3% fibrin gels. Morphometric analysis confirmed that 50–75% of cultured vein disks developed radial capillary growth within 15 days. Sst 2 gene expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) analysis of the RNA from veins before culture and from tissue-matched vein disks that exhibited an angiogenic response. The sst 2 gene was expressed in the proliferating angiogenic sprouts of human vascular endothelium. The presence of sst 2 receptors on proliferating angiogenic vessels was confirmed by immunohistochemical staining and in vivo scintigraphy. These results suggest that sst 2 may be a unique target for antiangiogenic therapy with sst 2 preferring somatostatin analogues conjugated to radioisotopes or cytotoxic agents. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albers AR, O’Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, Hoeger C, Rivier J, Wenger GD, O’Dorisio TM and Qualman SJ (2000) Somatostatin receptor gene expression in neuroblastoma. Reg Peptides 88: 61–73
Balster DA, O’Dorisio MS, Summers MA and Turman MA (2001) Segmental expression of somatostatin receptor subtypes sst 1 and sst 2 in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 280, 3F457–F465
Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Hill N and Fletcher WS (1993) Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 55: 446–453
Bhatena SJ, Louis J, Schechter GP, Redman RS, Wahl L and Recant L (1981) Identification of human leukocytes bearing receptors for somatostatin and glucagon. Diabetes 30: 127–131
Bootsma A, van Eijck CH, Schouten KK, Reubi JC, Waser B, Foekens JA, van Pel R, Zwarthoff E, Lamberts SW and de Klein A (1993) Somatostatin receptor-positive primary breast tumors: genetic, patient and tumor characteristics. Int J Cancer 54: 357–361
Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD and Parish CR (1996) Novel in vitroassay for human angiogenesis. Lab Invest 75: 539–541
Conway MD, Sonmez M, Yank D, Woltering EA and Peyman GA (1996) Inhibition of corneal angiogenesis by octreotide acetate (OA) in a rabbit micropocket model. Invest Ophthalmol Vis Sci 37: 5547–5548
Cuntz MC, Levine EA, O’Dorisio TM, Watson JC, Wray DA, Espenan GD, McKnight CA, Meier JR, Weber LJ, Mera R, O’Dorisio MS and Woltering EA (1999) Intraoperative gamma detection of125I-lanreotide in women with primary breast cancer. Ann Surg Oncol 6: 367–370
Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci O, Campagni A and Tacca MD (1997) Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201–995). Clin Cancer Res 3: 263–267
Denzler B and Reubi JC (1999) Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 85, 1188–198
Espenan GD, Nelson JA, Fisher DR, Diaco DS, McCarthy KE, Anthony LB, Maloney TJ and Woltering EA (1999) Experiences with high-dose radiopeptide therapy: the health physics perspective. Health Physics 76: 225–231
Kalkner KM, Nilsson S and Westlin JE (1998) [111In-DTPA-D-Phel]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study. Anticancer Research 18, 1B513–516
Martinez DA, O’Dorisio MS and O’Dorisio TM (1995) Intraoperative detection and resection of occult neuroblastoma: a technique exploiting somatostatin receptor expression. J Pediat Surg 30: 1580–1585
McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ and Anthony CT (1998) in situ radiotherapy with111In-pentetreotide: initial observations and future directions. The CJSci American 4: 94–99
Meyers MO, Anthony CT, Coy DH, Murphy WA, Drouant GJ, Fuselier J, Espenan GD, Maloney TJ and Woltering EA (1998) Multiply radioiodinated somatostatin analogs induce receptor-specific cytotoxicity. J Surg Res 76: 154–157
Nilsson S, Reubi JC, Kalkner KM, Laissue JA, Horisberger U, Olerud C and Westlin JE (1995) Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualizedin vivoby [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res, (55), 5805s–5810s
O’Dorisio MS, Chen F, Wray DA, Qualman SJ and O’Dorisio TM (1994) Identification of somatostatin receptors on human neuroblastoma tumors. Cell Growth and Differentiation 5: 1–8
Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D and Woltering EA (1994) Post-receptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116: 1148–1154
Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F and Halmos G (2000) Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60: 2996–3001
Reubi JC, Horisberger U and Laissue JA (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interactions?. Int J Cancer 56: 681–689
Reubi JC, Schaer JC, Laissue JA and Waser B (1996) Somatostatin receptors and their subtypes in human tumors and peritumoral vessels. Metabolism: Clinical and Experimental 8: 39–49
Schirmer WJ, O’Dorisio TM, Schirmer TP, Mojzisik CM, Hinkle GH and Martin EW (1993) Intraoperative localization of neuroendocrine tumors with125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surg 114: 745–749
Thompson CS, O’Dorisio TM and Woltering EA (1986) Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Digestion 27: 62–65
van Hagen PM, Markusse HM, Lamberts SWJ, Kwekkenboom DJ, Reubi JC and Krenning EP (1994) Somatostatin receptor imaging: the presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 37: 1521–1528
Watson JC, Gebhardt BM, Alperin-Lea RC, Redmann JC and Woltering EA (1996) Initiation ofkdrgene transcription is associated with the conversion of human vascular endothelium to an angiogenic phenotype. Surg Forum 47: 462–466
Woltering EA, Ellison EC, O’Dorisio TM, Sparks J, Howe B and Dyben T (1986) Somatostatin-like peptides alter calcium but not secretin sensitivity of gastrinoma cells. J Surg Res 40: 605–608
Woltering EA, Barrie R, O’Dorisio TM, Arce D, Ure C, Cramer A, Holmes D, Roberston J and Fassler J (1991) Somatostatin analogs inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50: 245–251
Woltering EA, Barrie R, O’Dorisio TM, O’Dorisio MS, Nance R and Cook DM (1994) Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surg 116, 61139–1141
Woltering EA, O’Dorisio MS and O’Dorisio TM (1995) The role of somatostatin analogs in the management of cancer patients. Principles and Practice of Oncology Updates, DeVita VT Jr (ed) pp. 31–47, Lippincott Healthcare Publications: Philadelphia
Woltering EA, Alperin-Lea RC, Sharma C, Keenan EJ, Kurozawa D and Barrie R (1997) Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15: 77–88
Woltering EA, O’Dorisio MS, Murphy WA, Chen F, Drouant GJ, Espenan GD, Fisher DR, Sharma C, Diaco DS, Maloney TJ, Fuselier J, Nelson JA, O’Dorisio TM and Coy DH (1999) Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs. J Peptide Res 53: 201–206
Wynick D and Bloom SR (1991) The use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Endocrinol Metabol 73: 1–4
Zamora PO, Marek MJ and Knapp FF Jr (1997) Preparation of 188Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy. Appl Rad & Isotopes 48, 3305–309
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Watson, J., Balster, D., Gebhardt, B. et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 85, 266–272 (2001). https://doi.org/10.1054/bjoc.2001.1881
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1881
Keywords
This article is cited by
-
Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case report
European Journal of Hybrid Imaging (2022)
-
Pharmacokinetic analysis of [68Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2
European Journal of Nuclear Medicine and Molecular Imaging (2020)
-
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets
Infectious Agents and Cancer (2014)
-
A Study of Pipeline Drugs in Neuroendocrine Tumors
Journal of Gastrointestinal Cancer (2012)
-
Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin
Naunyn-Schmiedeberg's Archives of Pharmacology (2011)
